The Justice Department has ratcheted up the scrutiny of drug-pricing practices with a new round of inquiries over how pharmaceutical companies report product prices to the government Medicaid program.
The U.S. Attorney’s Office for the Eastern District of Pennsylvania and the Justice Department’s civil division are seeking information from Valeant Pharmaceuticals International Inc. and Eli Lilly & Co. about how they calculate and report drug prices for the Medicaid rebate program, the companies disclosed in filings to the Securities and Exchange Commission in recent weeks.
Read Full Article »